Can you tell me when apotex's ruxolitinib received approval?

Apotex’s generic version of ruxolitinib (the drug sold under the brand name Jakafi) was approved by the U.S. Food and Drug Administration on September 21, 2021. This approval allows Apotex to market the generic medication for the same indications as the original product—primarily myelofibrosis and polycythemia vera.